Eighteen deep technology companies building the next generation of energy, computing, and health infrastructure. All backed at the seed stage alongside co-investors across Europe.
Munich-based pioneer in closed-loop lithium-ion battery recycling. tozero's hydrometallurgical process recovers battery-grade lithium, nickel, cobalt, and manganese at over 95% purity, reducing dependence on primary mining and enabling a circular economy for EV batteries at industrial scale.
Germany • Seed Round, 2022 • Co-invested alongside Verve Ventures
Swiss carbon removal company permanently storing biogenic CO₂ in recycled concrete and demolition rubble through mineralisation. Each tonne of aggregates treated locks in approximately 10 kg of CO₂ permanently — turning waste concrete into a carbon sink. Operating commercial removal sites across Switzerland, Germany, and the UK.
Switzerland • Seed Round, 2021 • Co-invested alongside Verve Ventures, SET Ventures
Copenhagen-based company developing thermally driven direct air capture technology using solid sorbents and industrial waste heat. Phlair's modular systems are designed to integrate with existing industrial heat sources, dramatically lowering the energy cost of atmospheric CO₂ removal versus conventional DAC approaches requiring dedicated electricity inputs.
Denmark • Seed Round, 2023 • Co-invested alongside Verve Ventures
Berlin-based power-to-X company converting renewable electricity into carbon-neutral methanol and synthetic natural gas for industrial decarbonisation. Turn2X's modular reactor units can be deployed at wind and solar generation sites, providing a chemical storage pathway for excess renewable electricity and displacing fossil feedstocks in hard-to-abate sectors.
Germany • Seed Round, 2022 • Co-invested alongside Verve Ventures, UVC Partners
Dresden-based clean energy company and European leader in high-temperature solid oxide electrolyser cells (SOEC). Sunfire's technology achieves the highest electrical efficiency of any electrolyser technology at 84% (LHV), and its reversible SOEC system can switch between hydrogen production and power generation. Raised €215M in Series E funding in 2023 to scale manufacturing capacity.
Germany • Seed-to-Growth Co-investment, 2022 • Partners include Carbon Direct Capital, Lightrock
Munich-based fusion energy company spun out of the Max Planck Institute for Plasma Physics, developing compact stellarator fusion reactors. Unlike tokamaks, stellarators operate in a continuous steady-state, avoiding the disruption risk that plagues pulsed fusion designs. Proxima raised €7M seed in 2022 and €20M Series A in 2024, targeting a pilot plant by the early 2030s.
Germany • Seed Round, 2022 • Co-invested alongside Speedinvest, UVC Partners
Espoo-based company building on-premises superconducting quantum computers for research institutions and commercial operators. IQM's co-design approach — optimising hardware, software, and applications jointly — has enabled consistent improvements in qubit fidelity. The company raised €128M in total funding through 2023 and operates quantum systems at European supercomputing centres including the Leibniz Supercomputing Centre in Germany.
Finland • Seed Co-investment, 2019 • Investors include MIG Capital, Tesi, OpenOcean
Paris-based quantum computing company using neutral rubidium atoms trapped by optical tweezers as its qubit platform. Pasqal demonstrated a 100-qubit processor in 2021 and has since scaled to 1,000-qubit systems. Its analogue-digital quantum processing approach is particularly well-suited to quantum simulation of molecular systems relevant to materials science and drug discovery. Raised €100M Series B in 2023 led by Quantonation and GAIA.
France • Seed Co-investment, 2020 • Investors include Quantonation, Runa Capital, Daphni
Oxford-based quantum computing company developing superconducting qubit processors with a proprietary 3D chip architecture that dramatically reduces crosstalk between qubits. OQC's Toshiko processor, deployed via AWS Braket, delivers industry-leading two-qubit gate fidelities of 99.4%. Raised $100M Series B in 2022 to expand its cloud quantum computing service and accelerate hardware development.
United Kingdom • Seed Co-investment, 2018 • Investors include Oxford Sciences Enterprises, Lansdowne Partners
San Sebastián and London-based quantum software company developing quantum and quantum-inspired algorithms for optimisation problems in finance, energy, and manufacturing. Multiverse's CompactifAI product uses tensor network compression to reduce large language model sizes by up to 80% without significant accuracy loss, bridging quantum-inspired methods to classical AI applications. Raised €25M in 2024 to scale commercial deployments.
Spain / United Kingdom • Seed Co-investment, 2019 • Investors include JME Ventures, Quantonation
Zurich-based company developing photonic interposers that allow chipmakers to interconnect multiple processor chiplets with optical rather than electrical connections. ncodiN's platform enables supercomputer-level compute capacity in a single package with a fraction of the power consumption, directly addressing the interconnect bottleneck that limits multi-chiplet AI accelerator designs. Backed at seed stage by Verve Ventures.
Switzerland • Seed Round, 2022 • Co-invested alongside Verve Ventures
ETH Zurich spin-out developing electrohydrodynamic inkjet nanoprinting technology for semiconductor and display manufacturing. Scrona's EHD inkjet heads print functional materials with sub-micron resolution — enabling metal line widths and pixel pitches unachievable with conventional inkjet approaches — at a fraction of the cost of photolithographic processes. Applications span LED micro-displays, advanced packaging, and printed electronics.
Switzerland • Seed Round, 2016, Series A 2020 • Co-invested alongside Verve Ventures
London-based AI-first drug discovery company founded by genomics and machine learning experts from the Wellcome Sanger Institute and DeepMind. Relation builds cell foundation models from single-cell multi-omics data to predict how genetic perturbations affect disease biology — enabling rational selection of drug targets before any chemistry is run. Raised $25M seed in 2024 from Arch Venture Partners and GV.
United Kingdom • Seed Co-investment, 2024 • Investors include Arch Venture Partners, GV (Google Ventures)
Lund-based cancer diagnostics company using ultra-sensitive single-molecule sequencing to detect and monitor cancer from a simple blood draw. Saga's proprietary error-correction technology achieves variant allele frequencies as low as 0.001%, enabling detection of minimal residual disease and early relapse months ahead of conventional imaging. Targeting colorectal, lung, and breast cancer monitoring markets.
Sweden • Seed Round, 2021 • Investors include Industrifonden, Sunstone Life Science Ventures
London-based company running decentralised clinical trials entirely through a smartphone platform, from recruitment and consent through protocol delivery, data collection, and analysis. Lindus has demonstrated 5x faster recruitment than traditional site-based trials and 60% lower cost per patient. Raised $18M Series A in 2023 from Lakestar and Khosla Ventures to expand US and European clinical operations.
United Kingdom • Seed Co-investment, 2021 • Investors include Lakestar, Khosla Ventures
Cambridge-based allogeneic cell therapy company engineering lymphoid progenitor cells — rather than T cells or NK cells — as the starting material for CAR-based cancer immunotherapy. Appia's approach generates a broader repertoire of tumour-killing cell types from a single manufacturing run, potentially addressing solid tumour targets that have resisted T-cell based approaches. Raised $30M Series A in 2024 from Syncona and Foresite Capital.
United Kingdom • Seed Co-investment, 2022 • Investors include Syncona, Foresite Capital
Munich-based biotech developing small molecule drugs targeting ion channels in the nervous system for treatment-resistant pain and neurological diseases. Ion channels represent roughly 15% of all drug targets yet are dramatically underexploited by the pharmaceutical industry due to the historical difficulty of achieving channel-subtype selectivity. Enedra's structure-guided medicinal chemistry platform addresses this challenge directly.
Germany • Seed Round, 2022 • Investors include b.value, Bayern Kapital
Luxembourg and New York-based company applying machine learning to predict the probability of success for clinical drug development programmes. Intelligencia's platform ingests historical clinical trial data, biomarker information, competitive landscape, and regulatory precedent to generate probability-of-technical-success (PTRS) scores that allow pharmaceutical companies and investors to allocate capital more efficiently across development portfolios.
Luxembourg / United States • Seed Co-investment, 2020 • Investors include LifeSci Venture Partners, M Ventures